NCT00963235View on ClinicalTrials.gov

Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

PHASE3CompletedINTERVENTIONAL
Enrollment

331

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
HIV InfectionsPneumococcal Infections
Interventions
BIOLOGICAL

13-valent pneumococcal conjugate vaccine

Three doses of 13vPnC given 6 months apart.

PROCEDURE

Blood draw

Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.

Trial Locations (15)

10011

Pfizer Investigational Site, New York

10016

Pfizer Investigational Site, New York

10029

Pfizer Investigational Site, New York

10032

Pfizer Investigational Site, New York

10065

Pfizer Investigational Site, New York

14642

Pfizer Investigational Site, Rochester

20009

Pfizer Investigational Site, Washington D.C.

37604

Pfizer Investigational Site, Johnson City

40536

Pfizer Investigational Site, Lexington

63110

Pfizer Investigational Site, St Louis

75246

Pfizer Investigational Site, Dallas

78705

Pfizer Investigational Site, Austin

80045

Pfizer Investigational Site, Aurora

94115

Pfizer Investigational Site, San Francisco

01199

Pfizer Investigational Site, Springfield

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY